Propanc Biopharma publishes pilot study showing PRP proenzyme combo cuts tumor weight and extends survival
Propanc Biopharma reported a peer‑reviewed pilot study in Scientific Reports that tested its fixed‑ratio PRP formulation (Trypsinogen: Chymotrypsinogen A = 1: 6) across 24 human cancer cell lines. In orthotopic animal models the daily IV dose cut mean tumor weight by 85.9% in a pancreatic model and about 50% in an ovarian model, and a compassionate‑use cohort of 46 advanced‑cancer patients showed a mean survival of 9.0 months versus an expected 5.6 months, with no treatment‑related adverse events. The company said the data support moving PRP into a Phase 1b trial slated for the first quarter of 2027 and suggest the formulation may also re‑sensitize chemotherapy‑resistant pancreatic cells.
Why it matters
The company indicated the results will allow it to initiate a Phase 1b trial in Q1 2027, advancing PRP toward regulatory approval and potentially expanding its oncology pipeline.
Key facts
- 1The PRP formulation used a fixed‑ratio combination of Trypsinogen and Chymotrypsinogen A at 1: 6. investing.com
- 2The study evaluated the formulation across 24 human cancer cell lines. investing.com
- 3In an orthotopic pancreatic animal model, daily IV administration reduced mean tumor weight by 85.9%. investing.com
- 4In an orthotopic ovarian animal model, the same regimen achieved approximately 50% tumor‑weight inhibition. investing.com
- 5A compassionate‑use cohort of 46 advanced‑cancer patients showed a mean survival of 9.0 months versus a mean expected survival of 5.6 months. investing.com
- 6No treatment‑related adverse clinical events were reported in the preclinical or patient data. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.